Scopus Biopharma Inc
SCPS.OQ- Latest Trade
- trading lower0.36USD
- Change
- -0.04
- % Change
10.00%Negative
- Day Range
- 0.36 - 0.41
- 52-Week Range
- 0.34 - 7.44
As of Jun 24 2022. Values delayed up to 15 minutes
- Previous Close
- 0.40
- Open
- 0.39
- Volume
- 30,348.00
- 3 Month Average Trading Volume
- 1.68
- Shares Out (Mil)
- 21.09
- Market Cap
- 8.44
- Forward P/E
- -99,999.99
- Dividend Yield
- -99,999.99
Key Statistics
mean rating - analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- -99,999.99
- Price To Book (Quarterly)
- -99,999.99
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- -99,999.99
- Long Term Debt/Equity (Quarterly)
- -99,999.99
- Return On Investment (TTM)
- -1,559.60
- Return On Equity (TTM)
- -426.28
2021 (millions USD)
About Scopus Biopharma Inc
Company Information
Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of its immuno-oncology programs. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The Company is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Its pipeline also includes MRI-1867, which is a cannabinoid receptor mediating compound for the treatment of systemic sclerosis.
Address
420 Lexington Ave Rm 300NEW YORK, NY
10170-0399
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Joshua R. Lamstein
- Chairman of the Board, Principal Executive Officer
- Robert J. Gibson
- Vice Chairman of the Board, Treasurer, Secretary
- Alan M. Horsager
- President - Immuno-Oncology and President and Chief Executive Officer of Duet BioTherapeutics
- Aharon Schwartz
- Executive Chairman of Scopus BioPharma Israel Ltd
- Ira Scott Greenspan
- Director
- David S. Battleman
- Independent Director
- David A. Buckel
- Independent Director
- Raphael Hofstein
- Independent Director
- David Weild
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,825.70 | -- |
| Copper | 693.65 | 0.33%Negative |
| Brent Crude Oil | 113.12 | -- |
| CBOT Soybeans | 1,609.00 | 0.99%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,911.74 | 3.06%Positive |
| Euro STOXX 50 | 3,533.17 | 2.82%Positive |
| FTSE 100 | 7,208.81 | 2.68%Positive |
| Nikkei 225 | 26,491.97 | 1.23%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes